Core Insights - Sanara MedTech reported record annual revenue of $103.1 million in 2025, marking a 19% increase year over year, while achieving improved profitability metrics and operational performance [3][4][7]. Financial Performance - The company generated $6.8 million in cash from operations in 2025, a significant improvement from a cash usage of $24,000 in 2024, attributed to better operating performance and working capital management [1]. - Gross margin improved by approximately 200 basis points to 93% for the full year, with adjusted EBITDA rising by $7.9 million, or 86%, to $17 million [2][7]. - The net loss from continuing operations decreased by $1.5 million, or 80%, compared to the previous year [2]. Revenue Breakdown - For the fourth quarter of 2025, net revenue was $27.5 million, up 5% year over year, primarily driven by sales of soft tissue products [7][8]. - Excluding the impact of prior year sales related to Hurricane Helene, fourth-quarter 2025 net revenue increased by 13% year over year [8]. Commercial Strategy - The company ended 2025 with over 450 contracted distributors, up from over 350 at the end of 2024, and achieved sales in over 1,450 healthcare facilities [9][10]. - Sanara secured an Innovative Technology contract from Vizient, providing access to approximately 1,800 healthcare facilities [12]. Operational Updates - The wind-down of the Tissue Health Plus (THP) segment is substantially complete, with no material cash expected going forward [5][11]. - The company anticipates no material cash spend related to THP and reaffirmed its 2026 net revenue guidance of $116 million to $121 million, representing expected growth of approximately 13% to 17% [5][20]. Clinical and Intellectual Property Developments - Sanara is focused on building clinical evidence, with studies demonstrating the efficacy of its products, including BIASURGE and ALLOCYTE Plus [13]. - The company converted 11 provisional patent applications into non-provisional filings and submitted additional applications for international protection [14]. Future Outlook - The company expects first-quarter 2026 net revenue of approximately $26.7 million to $27.2 million, implying expected year-over-year growth of about 14% to 16% [20]. - Management emphasized the importance of educating facilities on the Vizient contract for future growth [21].

Financial Performance - The company achieved net revenue of $103.1 million for the full year 2025, marking a 19% year-over-year growth and exceeding $100 million for the first time in its history [4] - Gross margins expanded by approximately 200 basis points to 93% for the full year 2025, with a significant reduction in net loss from continuing operations by 80% to $1.5 million [5] - Adjusted EBITDA improved by 86% to $17 million for the full year 2025, and cash provided by operations was $6.8 million compared to cash used in operations of $24,000 in 2024 [5][26] Business Line Performance - In Q4 2025, net revenue was $27.5 million, representing a 5% year-over-year growth, primarily driven by sales of soft tissue products [7] - Excluding $1.8 million of BIASURGE sales from the previous year, Q4 2025 net revenue increased by 13% year-over-year [8] - The company ended 2025 with over 450 contracted distributors, up from over 350 at the end of 2024, indicating significant growth in its distributor network [9] Market Performance - The company successfully sold into over 1,450 healthcare facilities by the end of 2025, up from over 1,300 in 2024, with products contracted or approved for sale in over 4,000 facilities [10] - The surgeon customer base saw strong year-over-year growth, with ongoing efforts to penetrate existing facilities further [11] Company Strategy and Industry Competition - The company is focused on the surgical market, having ceased operations in the Tissue Health Plus segment, and aims to be a leaner, pure-play surgical company [12][13] - The BIASURGE product received an Innovative Technology contract from Vizient, providing access to approximately 1,800 healthcare facilities, which is expected to significantly enhance growth opportunities [15] - The company is committed to expanding its IP portfolio and has made progress in securing patent applications for its products [18] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning as a focused surgical company with a strong commercial strategy and significant growth potential in 2026 [30][31] - The company anticipates full-year 2026 net revenue to range from $116 million to $121 million, representing growth of approximately 13% to 17% compared to 2025 [27] Other Important Information - The company is investing in its field sales team and R&D initiatives to support future growth, with a focus on enhancing its surgical product portfolio [32][33] - The OsStic product is expected to be introduced to the U.S. market in Q1 2027, representing a significant opportunity in the bone fusion market [19][20] Q&A Session Summary Question: Growth attribution to BIASURGE following the Vizient contract - Management acknowledged the significance of the Vizient contract and indicated that while it will take time to educate facilities, it provides a strong growth runway for 2026 and beyond [37][38] Question: Impact of CellerateRX growth and upcoming studies - Management emphasized the importance of clinical evidence for CellerateRX and expressed confidence that the economic study will enhance relationships with hospitals, positively impacting future numbers [39][40][41]

Financial Performance - The company achieved net revenue of $103.1 million for the full year 2025, marking a 19% year-over-year growth and exceeding $100 million for the first time in its history [4] - Gross margins expanded by approximately 200 basis points to 93% for the full year 2025, with a significant reduction in net loss from continuing operations by 80% to $1.5 million [5] - Adjusted EBITDA improved by 86% to $17 million for the full year 2025, and cash provided by operations was $6.8 million compared to cash used in operations of $24,000 in 2024 [5][26] Business Line Performance - In Q4 2025, net revenue was $27.5 million, representing a 5% year-over-year growth, primarily driven by sales of soft tissue products [6] - Excluding $1.8 million of BIASURGE sales from the previous year, Q4 2025 net revenue increased by 13% year-over-year [8] - The company ended 2025 with over 450 contracted distributors, up from over 350 at the end of 2024, indicating significant growth in its distributor network [9] Market Performance - The company successfully sold into over 1,450 healthcare facilities by the end of 2025, up from over 1,300 in 2024, with products contracted or approved for sale in over 4,000 facilities [10] - The surgeon customer base saw strong year-over-year growth, with new users added across various specialties, although penetration within existing facilities remains low [11] Strategic Direction - The company is focused on the surgical market, having ceased operations of the Tissue Health Plus segment, and aims to bring innovative products to the operating room [12][13] - The BIASURGE product received an Innovative Technology contract from Vizient, providing access to approximately 1,800 healthcare facilities [15] - The company plans to introduce the OsStic synthetic injectable bone bioadhesive to the U.S. market in Q1 2027, which is expected to be a significant addition to its product portfolio [19][20] Management Commentary - Management expressed confidence in the company's positioning as a focused, pure-play surgical company with a commitment to driving growth through its commercial strategy [30][32] - The company anticipates full-year 2026 net revenue to range from $116 million to $121 million, representing a growth of approximately 13%-17% compared to 2025 [27] - Management highlighted the importance of clinical evidence and economic studies in strengthening relationships with healthcare facilities and driving product adoption [41][42] Other Important Information - The company is investing in its field sales team and R&D initiatives to support growth and enhance its competitive position in the surgical market [33][34] - The company has made significant progress in expanding its intellectual property portfolio, converting provisional patent applications into non-provisional filings [18] Q&A Session Summary Question: Impact of Vizient contract on growth - Management acknowledged the significance of the Vizient contract and indicated that it would take time to educate facilities, but it provides a strong growth opportunity for 2026 [39][40] Question: CellerateRX growth and reimbursement - Management emphasized the importance of clinical evidence for CellerateRX and expressed confidence that the economic study would enhance relationships with facilities and positively impact growth [41][42]

Financial Performance - The company achieved net revenue of $103.1 million for the full year 2025, marking a 19% year-over-year growth and exceeding $100 million for the first time in its history [4] - Gross margins expanded by approximately 200 basis points to 93% for the full year 2025, with a significant reduction in net loss from continuing operations by 80% to $1.5 million [5] - Adjusted EBITDA improved by 86% to $17 million for the full year 2025, and cash provided by operations was $6.8 million compared to cash used in operations of $24,000 in 2024 [5][26] Fourth Quarter Performance - In Q4 2025, net revenue was $27.5 million, representing a 5% year-over-year growth, with a 13% increase when excluding $1.8 million of BIASURGE sales from Q4 2024 [7][8] - Gross profit for Q4 increased by $1.6 million or 7% to $25.7 million, with gross margin at 93% [23][24] - Operating income for Q4 was $1.1 million, down from $2.3 million last year, primarily due to a non-cash impairment charge [24][25] Business Lines and Market Data - The company focused on three key commercial initiatives: strengthening relationships with independent distributors, selling into new healthcare facilities, and expanding within existing facilities [8][10] - The distributor network grew to over 450 contracted distributors by the end of 2025, up from over 350 in 2024 [9] - The company successfully sold into over 1,450 healthcare facilities by the end of 2025, compared to over 1,300 in 2024 [10] Strategic Direction and Industry Competition - The company is transitioning to a pure-play surgical company, focusing exclusively on the surgical market and ceasing operations of the Tissue Health Plus segment [12][21] - The strategic priorities for 2026 include penetrating the surgical wound market, targeted investments in the surgical product portfolio, and bringing the OsStic product to market [31][34] - The company aims to leverage its differentiated products to address a multi-billion-dollar annual opportunity in the surgical market [30] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning as it enters 2026, emphasizing the strength of its commercial model and the potential for continued growth [30][31] - The company anticipates net revenue for 2026 to range from $116 million to $121 million, representing growth of approximately 13% to 17% compared to 2025 [27][29] - Management highlighted the importance of clinical evidence and economic studies in supporting product growth and reimbursement opportunities [39][40] Other Important Information - The company secured an Innovative Technology contract from Vizient for its BIASURGE product, providing access to approximately 1,800 healthcare facilities [15] - Significant progress was made in expanding the intellectual property portfolio, with multiple patent applications submitted [18] - The company is on track to introduce the OsStic synthetic injectable bone bioadhesive to the U.S. market in Q1 2027 [19][20] Q&A Session Summary Question: Growth attribution to the Vizient contract for BIASURGE - Management acknowledged the significance of the Vizient contract and indicated that it would take time to educate facilities, but it provides a strong growth runway for 2026 and beyond [37][38] Question: Impact of new studies on CellerateRX growth - Management emphasized the importance of clinical and economic evidence for CellerateRX, stating that it strengthens relationships with hospitals and is expected to positively impact future numbers [39][41]

Financial Performance - The company achieved net revenue of $103.1 million for the full year 2025, marking a 19% year-over-year growth and exceeding $100 million for the first time in its history [4] - Gross margins expanded by approximately 200 basis points to 93% for the full year 2025, with a significant reduction in net loss from continuing operations by 80% to $1.5 million [5] - Adjusted EBITDA improved by 86% to $17 million for the full year 2025, and cash provided by operations was $6.8 million compared to cash used in operations of $24,000 in 2024 [5][26] Quarterly Performance - In Q4 2025, net revenue was $27.5 million, representing a 5% year-over-year growth, and a 13% increase when excluding $1.8 million of BIASURGE sales from Q4 2024 [6][8] - Gross profit for Q4 increased by $1.6 million or 7% to $25.7 million, with gross margin at 93% [23][24] - Operating income for Q4 was $1.1 million, down from $2.3 million last year, but increased to $2.9 million when excluding a non-cash impairment charge [24][25] Business Lines and Market Data - The growth in net revenue was primarily driven by sales of soft tissue products, with modest contributions from bone fusion products [6][8] - The company ended 2025 with over 450 contracted distributors, up from over 350 at the end of 2024, indicating a significant expansion of its distributor network [9] - The company achieved its target of selling into over 1,450 healthcare facilities by the end of 2025, compared to over 1,300 in 2024 [10] Company Strategy and Industry Competition - The company is focused on the surgical market, having ceased operations of the Tissue Health Plus segment, and aims to be a leaner, pure-play surgical company [12][13] - Strategic priorities for 2026 include penetrating the surgical wound market, investing in the field sales team, and enhancing R&D initiatives [32][33] - The company is preparing for the U.S. commercialization of OsStic, a synthetic injectable bone bioadhesive, expected in Q1 2027, which is anticipated to be a significant addition to its product portfolio [19][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning as a focused surgical company with a strong commercial model and significant growth opportunities in the surgical market [31][36] - The company reaffirmed its full year 2026 net revenue guidance of $116 million to $121 million, representing a growth of approximately 13% to 17% compared to 2025 [27][30] Other Important Information - The company has made progress in expanding its intellectual property portfolio, converting 11 provisional patent applications into non-provisional filings [18] - Clinical studies supporting the efficacy of BIASURGE and ALLOCYTE Plus were highlighted, showcasing their effectiveness in preventing surgical site infections and promoting bone healing [16][17] Q&A Session Summary Question: Impact of Vizient contract on growth - Management acknowledged the significance of the Vizient contract and indicated that it would take time to educate facilities, but it provides a strong growth runway for 2026 and beyond [39][40] Question: CellerateRX growth and reimbursement - Management emphasized the importance of clinical evidence for CellerateRX and expressed confidence that the economic study would enhance relationships with hospitals and positively impact future numbers [41][42]

Financial Performance - For the full year 2025, the company achieved net revenue of $103.1 million, marking a 19% year-over-year growth and exceeding $100 million for the first time in its history [4] - Gross margins expanded by approximately 200 basis points to 93% for the full year 2025, with a significant reduction in net loss from continuing operations by 80% to $1.5 million [5] - The company generated $6.8 million of cash from operations in 2025, a substantial improvement from $24,000 used in operations in 2024 [5][25] Quarterly Performance - In Q4 2025, net revenue was $27.5 million, reflecting a 5% year-over-year growth, and a 13% increase when excluding $1.8 million of BIASURGE sales from Q4 2024 [6][7] - Gross profit for Q4 increased by $1.6 million or 7% to $25.7 million, with gross margin rising to 93% [22][23] - Adjusted EBITDA for Q4 was $4.7 million, compared to $4.1 million in the previous year [24] Business Lines and Market Data - The growth in net revenue was primarily driven by sales of soft tissue products, with contributions from bone fusion products [6] - The company ended 2025 with over 450 contracted distributors, up from over 350 at the end of 2024, indicating a significant expansion of its distributor network [9] - The company achieved its target of selling into over 1,450 healthcare facilities by the end of 2025, compared to over 1,300 in 2024 [10] Strategic Direction and Industry Competition - The company is focusing exclusively on the surgical market, having ceased operations in the Tissue Health Plus segment, which is now classified as discontinued operations [12][13] - The strategic priorities for 2026 include penetrating the surgical wound market, investing in the sales team and R&D, and bringing the OsStic product to market [31][34] - The company aims to leverage its differentiated products to address a multi-billion-dollar annual opportunity in the surgical market [30] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning as a focused surgical company, emphasizing the importance of clinical evidence and economic studies to support product adoption [39][40] - The company anticipates net revenue for 2026 to range from $116 million to $121 million, representing growth of approximately 13% to 17% compared to 2025 [26][29] Other Important Information - The company secured an Innovative Technology contract from Vizient for its BIASURGE product, which will provide access to approximately 1,800 healthcare facilities [15] - The R&D team is focused on expanding the IP portfolio and has converted 11 provisional patent applications into non-provisional filings [18] Q&A Session Summary Question: Growth attribution to the Vizient contract for BIASURGE - Management acknowledged the significance of the Vizient contract and indicated that it would take time to educate facilities, but it provides a strong growth runway for 2026 and beyond [37][38] Question: Impact of cost-effectiveness studies on CellerateRX growth - Management emphasized the importance of clinical and economic evidence for CellerateRX, stating that it strengthens relationships within hospitals and is expected to positively impact future numbers [39][40]

Sanara MedTech FY Conference Summary Company Overview - **Company Name**: Sanara MedTech (NasdaqCM: SMTI) - **Industry**: Medical Technology focused on surgical wound treatment - **CEO**: Seth Jahn - **CFO**: Elizabeth Taylor - **Market Cap**: $183 million - **Net Revenue (Trailing 12 months)**: Approximately $102 million - **EBITDA Margin**: Approximately $16 million - **Net Income from Continued Operations**: Approximately $1.6 million - **Contracted Facilities**: Over 4,000 across the U.S. [5][27] Core Business and Growth Strategy - **Focus**: Sanara MedTech specializes in innovative products for surgical wound treatment, particularly through its flagship product, CellerateRX, which is designed for use in the operating room (OR) [4][12]. - **Growth Rate**: The company has achieved a 51% compound annual growth rate (CAGR) in net revenue over the past seven years [4]. - **Market Position**: The company aims to target a total addressable market (TAM) of $1 billion with improved clinical outcomes [8]. - **Product Portfolio**: Key products include: - **CellerateRX**: A hydrolyzed surgical powder with a TAM of approximately $3.6 billion in the U.S. [13]. - **BIASURGE**: An antimicrobial wash that is the only no-rinse solution on the market [13]. - **OsStic**: A bioadhesive technology expected to launch in early 2027, which has received Breakthrough Device designation from the FDA [18][29]. Financial Performance and Projections - **2025 Preliminary Results**: Net revenue between $102 million and $103.2 million, representing a 19% increase [26]. - **2026 Revenue Guidance**: Projected net revenue between $116 million and $121 million, indicating a growth of 13% to 17% [27]. - **Cash Position**: $16.6 million at the end of 2025, with long-term debt of approximately $46 million [26]. Sales and Distribution Strategy - **Sales Model**: A hybrid model combining direct sales force and distributor partnerships, with over 400 distributor agreements in place [20][22]. - **Facility Access**: Currently doing business in 1,400 of the 4,000 contracted facilities, with plans to expand into the remaining 2,600 [23][25]. - **Key Drivers for Growth**: Focus on increasing surgeon users, expanding into vascular and plastics specialties, and enhancing education with distributor partners [25]. Research and Development - **Clinical Evidence**: Sanara emphasizes scientific, clinical, and economic evidence for its products, with over 20 published papers supporting CellerateRX [15][19]. - **Product Enhancements**: Ongoing R&D projects aimed at enhancing existing products and preparing for the commercialization of OsStic [29]. Market Positioning and Competitive Strategy - **Pricing Strategy**: Competitive pricing is a key component of the growth strategy, aiming to achieve standard of care through case volume rather than price increases [50]. - **M&A Strategy**: Future acquisitions will focus on complementary products that fit within the company's core offerings, avoiding a broad portfolio of small products [41][46]. Conclusion - Sanara MedTech is positioned for significant growth in the surgical wound treatment market, with a strong focus on innovative products, a solid financial foundation, and a clear strategy for expanding its market presence and product offerings [29].

Core Insights - Sanara MedTech Inc. reported a strong financial performance for Q3 2025, with net revenue growth of 22% year-over-year, driven primarily by a 24% increase in sales of surgical soft tissue products [3][6][10]. Financial Summary - Q3 2025 net revenue was $26.3 million, compared to $21.7 million in Q3 2024, marking an increase of $4.7 million [6][10]. - For the first nine months of 2025, net revenue reached $75.6 million, up 25% from $60.4 million in the same period of 2024 [10][16]. - Gross profit for Q3 2025 was $24.5 million, a 24% increase from $19.7 million in Q3 2024, with a gross margin of 93% [7][10]. - Operating income for Q3 2025 was $2.9 million, compared to $0.8 million in Q3 2024, reflecting a 278% increase [9][10]. Operational Developments - The company has ceased operations of its THP segment as part of a strategic realignment to enhance operational efficiency and focus on its core surgical business [3][5][10]. - The strategic realignment is expected to support sustained long-term growth and value creation [3][10]. Profitability Metrics - Net income from continuing operations for Q3 2025 was $0.8 million, compared to a net loss of $0.2 million in Q3 2024 [10][12]. - Adjusted EBITDA for Q3 2025 was $4.9 million, up from $2.6 million in Q3 2024, indicating improved profitability [10][13]. Cash Flow and Debt - As of September 30, 2025, the company had $14.9 million in cash and $45.1 million in long-term debt, compared to $15.9 million and $30.7 million, respectively, at the end of 2024 [14][10]. - Net cash provided by operating activities in Q3 2025 was $2.2 million, slightly up from $2.1 million in Q3 2024 [13][10].

Core Insights - Sanara MedTech Inc. reported a 28% year-over-year increase in net revenue for Q2 2025, reaching $25.8 million, driven by strong sales in its Sanara Surgical segment [5][8] - The company is evaluating strategic alternatives for its subsidiary, Tissue Health Plus, LLC, to maximize shareholder value while continuing to invest in its technology platform [4][12] Financial Performance - Q2 2025 net revenue increased to $25.8 million from $20.2 million in Q2 2024, a growth of $5.7 million or 28% [5][8] - For the first six months of 2025, net revenue rose 27% year-over-year to $49.3 million, compared to $38.7 million in the same period of 2024 [15] - The company reported a net loss of $2.0 million in Q2 2025, an improvement from a net loss of $3.5 million in Q2 2024 [12][16] - Adjusted EBITDA for Q2 2025 was $2.7 million, compared to $0.6 million in Q2 2024 [13] Segment Performance - The Sanara Surgical segment achieved a net income of $0.5 million in Q2 2025, a significant improvement from a net loss of $2.2 million in Q2 2024 [12] - The Tissue Health Plus segment reported a net loss of $2.5 million in Q2 2025, compared to a net loss of $1.3 million in Q2 2024 [12] - For the first six months of 2025, the Sanara Surgical segment generated Segment Adjusted EBITDA of $7.4 million, up from $2.5 million in the same period of 2024 [17] Revenue Breakdown - Sales of soft tissue repair products contributed $22.7 million in Q2 2025, up from $17.6 million in Q2 2024, marking a 28% increase [7][8] - Bone fusion products sales increased to $3.1 million in Q2 2025, a 25% rise from $2.5 million in Q2 2024 [7][8] Operating Expenses - Operating expenses for Q2 2025 were $23.9 million, an increase of 14% from $21.0 million in Q2 2024, primarily due to higher selling, general, and administrative expenses [10] - The gross profit for Q2 2025 was $23.9 million, reflecting a gross margin of 93%, up from 90% in Q2 2024 [9] Cash Flow and Debt - Cash flow from operating activities in Q2 2025 was $2.7 million, compared to cash used in operating activities of $1.4 million in Q2 2024 [14] - As of June 30, 2025, the company had $17.0 million in cash and $44.2 million in long-term debt, compared to $15.9 million and $30.7 million, respectively, at the end of 2024 [14]